Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: Clinical and molecular considerations

Current Medicinal Chemistry

Volumn 18, Issue 11, 2011, Pages 1613-1628

  Pallis, A ^a   Briasoulis, E ^b   Linardou, H ^c   Papadimitriou, C ^d   Bafaloukos, D ^c   Kosmidis, P ^e   Murray, S ^f,g  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e HYGEIA HOSPITAL   (Greece)

^f BioMarker Solutions   (United Kingdom)

^g GeneKOR ^*  (Greece)

Author keywords

BRAF; Erlotinib; Gefitinib; Her 2; Her 3; IGFR 1; KRAS; MET; NSCLC; Polymorphisms; PTEN; Resistance

Indexed keywords

AMPHIREGULIN; B RAF KINASE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; MOLECULAR MARKER; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER PATIENT; CLONE; EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE K RAS; RECEPTOR GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955692762     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795471383     Document Type: Article

References (184)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
2. Anonymous, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol., 2008, 26, 4617-4625.
3. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 2002, 346, 92-98. (Pubitemid 34438899)
4. Pallis, A.G.; Serfass, L.; Dziadziusko, R.; van Meerbeeck, J.P.; Fennell, D.; Lacombe, D.; Welch, J.; Gridelli, C. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur. J. Cancer, 2009, 45, 2473-2487.
5. Fedorov, O.; Muller, S.; Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Biol., 2010, 6, 166-169.
6. Hait, W.N.; Hambley, T.W. Targeted cancer therapeutics. Cancer Res., 2009, 69, 1263-1267; discussion 1267.
7. Veale, D.; Ashcroft, T.; Marsh, C.; Gibson, G.J.; Harris, A.L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer, 1987, 55, 513-516. (Pubitemid 17098858)
8. Ohtsuka, K.; Ohnishi, H.; Fujiwara, M.; Kishino, T.; Matsushima, S.; Furuyashiki, G.; Takei, H.; Koshiishi, Y.; Goya, T.; Watanabe, T. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer, 2007, 109, 741-750. (Pubitemid 46233236)
9. Suzuki, S.; Dobashi, Y.; Sakurai, H.; Nishikawa, K.; Hanawa, M.; Ooi, A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer, 2005, 103, 1265-1273. (Pubitemid 40328099)
10. Amann, J.; Kalyankrishna, S.; Massion, P.P.; Ohm, J.E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; Kim, Y.H.; Pollack, J.R.; Yanagisawa, K.; Gazdar, A.; Minna, J.D.; Kurie, J.M.; Carbone, D.P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res., 2005, 65, 226-235. (Pubitemid 40070814)
11. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated nonsmall- cell lung cancer. N. Engl. J. Med., 2005, 353, 123-132. (Pubitemid 41058344)
12. Wheatley-Price, P.; Ding, K.; Seymour, L.; Clark, G.M.; Shepherd, F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol., 2008, 26, 2350-2357.
13. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-1537. (Pubitemid 41540110)
14. Sanford, M.; Scott, L.J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs, 2009, 69, 2303-2328.
15. Chang, A.; Parikh, P.; Thongprasert, S.; Tan, E.H.; Perng, R.P.; Ganzon, D.; Yang, C.H.; Tsao, C.J.; Watkins, C.; Botwood, N.; Thatcher, N. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J. Thorac. Oncol., 2006, 1, 847-855. (Pubitemid 47181391)
16. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A. Jr.; Franklin, W.A.; Dziadziuszko, R.; Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J.R.; Ciuleanu, T.; von Pawel, J.; Watkins, C.; Flannery, A.; Ellison, G.; Donald, E.; Knight, L.; Parums, D.; Botwood, N.; Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol., 2006, 24, 5034-5042. (Pubitemid 46631407)
17. Lee, D.H.; Park, K.; Kim, J.H.; Lee, J.S.; Shin, S.W.; Kang, J.H.; Ahn, M.J.; Ahn, J.S.; Suh, C.; Kim, S.W. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin. Cancer Res., 2010, 16, 1307-1314.
18. Maruyama, R.; Nishiwaki, Y.; Tamura, T.; Yamamoto, N.; Tsuboi, M.; Nakagawa, K.; Shinkai, T.; Negoro, S.; Imamura, F.; Eguchi, K.; Takeda, K.; Inoue, A.; Tomii, K.; Harada, M.; Masuda, N.; Jiang, H.; Itoh, Y.; Ichinose, Y.; Saijo, N.; Fukuoka, M. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 4244-4252.
19. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J.J.; Chewaskulyong, B.; Jiang, H.; Duffield, E.L.; Watkins, C.L.; Armour, A.A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361, 947-957.
20. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; Fujita, Y.; Okinaga, S.; Hirano, H.; Yoshimori, K.; Harada, T.; Ogura, T.; Ando, M.; Miyazawa, H.; Tanaka, T.; Saijo, Y.; Hagiwara, K.; Morita, S.; Nukiwa, T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med., 2010, 362, 2380-2388.
21. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T.; Asami, K.; Katakami, N.; Takada, M.; Yoshioka, H.; Shibata, K.; Kudoh, S.; Shimizu, E.; Saito, H.; Toyooka, S.; Nakagawa, K.; Fukuoka, M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol., 2010, 11, 121-128.
22. Dahabreh, I.J.; Linardou, H.; Siannis, F.; Kosmidis, P.; Bafaloukos, D.; Murray, S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res., 2010, 16, 291-303.
23. Roukos, D.H.; Murray, S.; Briasoulis, E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol. Ther., 2007, 6, 308-312. (Pubitemid 47328293)
24. Linardou, H.; Dahabreh, I.J.; Bafaloukos, D.; Kosmidis, P.; Murray, S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat. Rev. Clin. Oncol., 2009, 6, 352-366.
25. Benedettini, E.; Sholl, L.M.; Peyton, M.; Reilly, J.; Ware, C.; Davis, L.; Vena, N.; Bailey, D.; Yeap, B.Y.; Fiorentino, M.; Ligon, A.H.; Pan, B.S.; Richon, V.; Minna, J.D.; Gazdar, A.F.; Draetta, G.; Bosari, S.; Chirieac, L.R.; Lutterbach, B.; Loda, M. Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis. Am. J. Pathol., 2010, 177, 415-423.
26. Takeda, M.; Okamoto, I.; Fujita, Y.; Arao, T.; Ito, H.; Fukuoka, M.; Nishio, K.; Nakagawa, K. De novo resistance to epidermal growth factor receptortyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J. Thorac. Oncol., 2010, 5, 399-400.
27. Jackman, D.; Pao, W.; Riely, G.J.; Engelman, J.A.; Kris, M.G.; Janne, P.A.; Lynch, T.; Johnson, B.E.; Miller, V.A. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol., 2010, 28, 357-360.
28. Xu, Y.; Liu, H.; Chen, J.; Zhou, Q. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol. Ther., 2010, 9.
29. Humtsoe, J.O.; Kramer, R.H. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene, 2010, 29, 1214-1226.
30. Galleges Ruiz, M.I.; Floor, K.; Steinberg, S.M.; Grunberg, K.; Thunnissen, F.B.; Belien, J.A.; Meijer, G.A.; Peters, G.J.; Smit, E.F.; Rodriguez, J.A.; Giaccone, G. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br. J. Cancer, 2009, 100, 145-152.
31. Luo, F.; Brooks, D.G.; Ye, H.; Hamoudi, R.; Poulogiannis, G.; Patek, C.E.; Winton, D.J.; Arends, M.J. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int. J. Exp. Pathol., 2009, 90, 558-574.
32. Schleger, C.; Heck, R.; Steinberg, P. The role of wild-type and mutated N-ras in the malignant transformation of liver cells. Mol. Carcinog, 2000, 28, 31-41. (Pubitemid 30252925)
33. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced nonsmall- cell lung cancer and metastatic colorectal cancer. Lancet Oncol., 2008, 9, 962-972.
34. Cortot, A.B.; Italiano, A.; Burel-Vandenbos, F.; Martel-Planche, G.; Hainaut, P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer, 2010, 116, 2682-2687.
35. Linardou, H.; Briasoulis, E.; Dahabreh, I.J.; Mountzios, G.; Papadimitriou, C.; Papadopoulos, S.; Bafaloukos, D.; Kosmidis, P.; Murray, S. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev., 2010, 37, 221-233.
36. Mascaux, C.; Iannino, N.; Martin, B.; Paesmans, M.; Berghmans, T.; Dusart, M.; Haller, A.; Lothaire, P.; Meert, A.P.; Noel, S.; Lafitte, J.J.; Sculier, J.P. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer, 2005, 92, 131-139. (Pubitemid 40188446)
37. Marchetti, A.; Milella, M.; Felicioni, L.; Cappuzzo, F.; Irtelli, L.; Del Grammastro, M.; Sciarrotta, M.; Malatesta, S.; Nuzzo, C.; Finocchiaro, G.; Perrucci, B.; Carlone, D.; Gelibter, A.J.; Ceribelli, A.; Mezzetti, A.; Iacobelli, S.; Cognetti, F.; Buttitta, F. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia, 2009, 11, 1084-1092.
38. Park, I.H.; Kim, J.Y.; Jung, J.I.; Han, J.Y. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest. New Drugs, 2009, 28, 791-799.
39. Blum, R.; Cox, A.D.; Kloog, Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov., 2008, 3, 31-47. (Pubitemid 351223208)
40. Ravoet, C.; Mineur, P.; Robin, V.; Debusscher, L.; Bosly, A.; Andre, M.; El Housni, H.; Soree, A.; Bron, D.; Martiat, P. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann. Hematol., 2008, 87, 881-885.
41. Sparano, J.A.; Moulder, S.; Kazi, A.; Coppola, D.; Negassa, A.; Vahdat, L.; Li, T.; Pellegrino, C.; Fineberg, S.; Munster, P.; Malafa, M.; Lee, D.; Hoschander, S.; Hopkins, U.; Hershman, D.; Wright, J.J.; Kleer, C.; Merajver, S.; Sebti, S.M. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin. Cancer Res., 2009, 15, 2942-2948.
42. Cichowski, K.; Janne, P.A. Drug discovery: inhibitors that activate. Nature, 2010, 464, 358-359.
43. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010, 464, 431-435.
44. Poulikakos, P.I.; Zhang, C.; Bollag, G.; Shokat, K.M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature, 2010, 464, 427-430.
45. Heidorn, S.J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010, 140, 209-221.
46. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4, 915-925.
47. Cappuzzo, F.; Janne, P.A.; Skokan, M.; Finocchiaro, G.; Rossi, E.; Ligorio, C.; Zucali, P.A.; Terracciano, L.; Toschi, L.; Roncalli, M.; Destro, A.; Incarbone, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M. MET increased gene copy number and primary resistance to gefitinib therapy in non-smallcell lung cancer patients. Ann. Oncol., 2009, 20, 298-304.
48. Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; Del Grammastro, M.; Sciarrotta, M.G.; Buttitta, F.; Incarbone, M.; Toschi, L.; Finocchiaro, G.; Destro, A.; Terracciano, L.; Roncalli, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol., 2009, 27, 1667-1674.
49. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316, 1039-1043. (Pubitemid 46799492)
50. Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Janne, P.A.; Joshi, V.A.; McCollum, D.; Evans, T.L.; Muzikansky, A.; Kuhlmann, G.L.; Han, M.; Goldberg, J.S.; Settleman, J.; Iafrate, A.J.; Engelman, J.A.; Haber, D.A.; Johnson, B.E.; Lynch, T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol., 2008, 26, 2442-2449.
51. Chen, H.J.; Mok, T.S.; Chen, Z.H.; Guo, A.L.; Zhang, X.C.; Su, J.; Wu, Y.L. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitorresistant Chinese non-small cell lung cancer. Pathol. Oncol. Res., 2009, 15, 651-658.
52. Yang, C.H.; Yu, C.J.; Shih, J.Y.; Chang, Y.C.; Hu, F.C.; Tsai, M.C.; Chen, K.Y.; Lin, Z.Z.; Huang, C.J.; Shun, C.T.; Huang, C.L.; Bean, J.; Cheng, A.L.; Pao, W.; Yang, P.C. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol., 2008, 26, 2745-2753.
53. Bean, J.; Brennan, C.; Shih, J.Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C.J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.F.; Yang, P.C.; Miller, V.; Ladanyi, M.; Yang, C.H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 20932-20937.
54. Rho, J.K.; Choi, Y.J.; Lee, J.K.; Ryoo, B.Y.; Na, II; Yang, S.H.; Lee, S.S.; Kim, C.H.; Yoo, Y.D.; Lee, J.C. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol. Cancer Res., 2009, 7, 1736-1743.
55. Yoshida, T.; Okamoto, I.; Okamoto, W.; Hatashita, E.; Yamada, Y.; Kuwata, K.; Nishio, K.; Fukuoka, M.; Janne, P.A.; Nakagawa, K. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci., 2010, 101, 167-172.
56. Okabe, T.; Okamoto, I.; Tsukioka, S.; Uchida, J.; Hatashita, E.; Yamada, Y.; Yoshida, T.; Nishio, K.; Fukuoka, M.; Janne, P.A.; Nakagawa, K. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin. Cancer Res., 2009, 15, 907-913.
57. Okamoto, W.; Okamoto, I.; Tanaka, K.; Hatashita, E.; Yamada, Y.; Kuwata, K.; Yamaguchi, H.; Arao, T.; Nishio, K.; Fukuoka, M.; Janne, P.A.; Nakagawa, K. TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation. Mol. Cancer Ther., 2010, 9, 2785-2792.
58. Bagai, R.; Fan, W.; Ma, P.C. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs, 2010, 13, 404-414.
59. Eder, J.P.; Shapiro, G.I.; Appleman, L.J.; Zhu, A.X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; McCallum, S.; Heath, E.I.; Boerner, S.A.; LoRusso, P.M. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res., 2010, 16, 3507-3516.
60. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; Mitsudomi, T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol., 2009, 4, 5-11.
61. Lim, E.H.; Zhang, S.L.; Li, J.L.; Yap, W.S.; Howe, T.C.; Tan, B.P.; Lee, Y.S.; Wong, D.; Khoo, K.L.; Seto, K.Y.; Tan, L.; Agasthian, T.; Koong, H.N.; Tam, J.; Tan, C.; Caleb, M.; Chang, A.; Ng, A.; Tan, P. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advancedstage non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2009, 4, 12-21.
62. Tan, Y.H.; Krishnaswamy, S.; Nandi, S.; Kanteti, R.; Vora, S.; Onel, K.; Hasina, R.; Lo, F.Y.; El-Hashani, E.; Cervantes, G.; Robinson, M.; Kales, S.C.; Lipkowitz, S.; Karrison, T.; Sattler, M.; Vokes, E.E.; Wang, Y.C.; Salgia, R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One, 2010, 5, e8972.
63. Hirsch, F.R.; Varella-Garcia, M.; Cappuzzo, F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 2009, 28(Suppl 1), S32-37.
64. Gandhi, J.; Zhang, J.; Xie, Y.; Soh, J.; Shigematsu, H.; Zhang, W.; Yamamoto, H.; Peyton, M.; Girard, L.; Lockwood, W.W.; Lam, W.L.; Varella-Garcia, M.; Minna, J.D.; Gazdar, A.F. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One, 2009, 4, e4576.
65. Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Hwang, P.G.; Im, S.A.; Lee, K.H.; Kim, J.H.; Kim, D.W.; Heo, D.S.; Kim, N.K.; Chung, D.H.; Bang, Y.J. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res., 2006, 12, 2538-2544.
66. Lee, W.; Jiang, Z.; Liu, J.; Haverty, P.M.; Guan, Y.; Stinson, J.; Yue, P.; Zhang, Y.; Pant, K.P.; Bhatt, D.; Ha, C.; Johnson, S.; Kennemer, M.I.; Mohan, S.; Nazarenko, I.; Watanabe, C.; Sparks, A.B.; Shames, D.S.; Gentleman, R.; de Sauvage, F.J.; Stern, H.; Pandita, A.; Ballinger, D.G.; Drmanac, R.; Modrusan, Z.; Seshagiri, S.; Zhang, Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature, 2010, 465, 473-477.
67. Swanton, C.; Futreal, A.; Eisen, T. Her2-targeted therapies in non-small cell lung cancer. Clin. Cancer Res., 2006, 12, 4377s-4383s. (Pubitemid 44197185)
68. Cappuzzo, F.; Bemis, L.; Varella-Garcia, M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N. Engl. J. Med., 2006, 354, 2619-2621. (Pubitemid 43882374)
69. Cappuzzo, F.; Toschi, L.; Domenichini, I.; Bartolini, S.; Ceresoli, G.L.; Rossi, E.; Ludovini, V.; Cancellieri, A.; Magrini, E.; Bemis, L.; Franklin, W.A.; Crino, L.; Bunn, P.A. Jr.; Hirsch, F.R.; Varella-Garcia, M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br. J. Cancer, 2005, 93, 1334-1340. (Pubitemid 41752859)
70. Buckingham, L.E.; Coon, J.S.; Morrison, L.E.; Jacobson, K.K.; Jewell, S.S.; Kaiser, K.A.; Mauer, A.M.; Muzzafar, T.; Polowy, C.; Basu, S.; Gale, M.; Villaflor, V.M.; Bonomi, P. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J. Thorac. Oncol., 2007, 2, 414-422. (Pubitemid 47181696)
71. Pao, W.; Miller, V.A.; Venkatraman, E.; Kris, M.G. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J. Natl. Cancer Inst., 2004, 96, 1117-1119. (Pubitemid 39207039)
72. Cappuzzo, F.; Toschi, L.; Tallini, G.; Ceresoli, G.L.; Domenichini, I.; Bartolini, S.; Finocchiaro, G.; Magrini, E.; Metro, G.; Cancellieri, A.; Trisolini, R.; Crino, L.; Bunn, P.A. Jr.; Santoro, A.; Franklin, W.A.; Varella- Garcia, M.; Hirsch, F.R. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol., 2006, 17, 1120-1127. (Pubitemid 43985248)
73. Morgillo, F.; Kim, W.Y.; Kim, E.S.; Ciardiello, F.; Hong, W.K.; Lee, H.Y. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res., 2007, 13, 2795-2803. (Pubitemid 46788049)
74. Guix, M.; Faber, A.C.; Wang, S.E.; Olivares, M.G.; Song, Y.; Qu, S.; Rinehart, C.; Seidel, B.; Yee, D.; Arteaga, C.L.; Engelman, J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest., 2008, 118, 2609-2619. (Pubitemid 351949788)
75. Tang, J.M.; He, Q.Y.; Guo, R.X.; Chang, X.J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung. Cancer, 2006, 51, 181-191.
76. Vivanco, I.; Rohle, D.; Versele, M.; Iwanami, A.; Kuga, D.; Oldrini, B.; Tanaka, K.; Dang, J.; Kubek, S.; Palaskas, N.; Hsueh, T.; Evans, M.; Mulholland, D.; Wolle, D.; Rajasekaran, S.; Rajasekaran, A.; Liau, L.M.; Cloughesy, T.F.; Dikic, I.; Brennan, C.; Wu, H.; Mischel, P.S.; Perera, T.; Mellinghoff, I.K. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 6459-6464.
77. Zhuang, H.Q.; Wang, J.; Yuan, Z.Y.; Zhao, L.J.; Wang, P.; Wang, C.L. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J. Exp. Clin. Cancer Res., 2009, 28, 123.
78. Sos, M.L.; Koker, M.; Weir, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A.F.; Minna, J.D.; Garraway, L.A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R.K. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res., 2009, 69, 3256-3261.
79. Araujo, A.; Ribeiro, R.; Azevedo, I.; Coelho, A.; Soares, M.; Sousa, B.; Pinto, D.; Lopes, C.; Medeiros, R.; Scagliotti, G.V. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. Oncologist, 2007, 12, 201-210.
80. Tiseo, M.; Capelletti, M.; De Palma, G.; Franciosi, V.; Cavazzoni, A.; Mozzoni, P.; Alfieri, R.R.; Goldoni, M.; Galetti, M.; Bortesi, B.; Bozzetti, C.; Loprevite, M.; Boni, L.; Camisa, R.; Rindi, G.; Petronini, P.G.; Ardizzoni, A. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 1104-1111.
81. Nie, Q.; Wang, Z.; Zhang, G.C.; An, S.J.; Lin, J.Y.; Guo, A.L.; Li, R.; Gan, B.; Huang, Y.; Mok, T.S.; Wu, Y.L. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur. J. Pharmacol., 2007, 570, 175-181. (Pubitemid 47247671)
82. Ma, F.; Sun, T.; Shi, Y.; Yu, D.; Tan, W.; Yang, M.; Wu, C.; Chu, D.; Sun, Y.; Xu, B.; Lin, D. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer, 2009, 66, 114-119.
83. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol., 2008, 26, 5705-5712.
84. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954. (Pubitemid 34716871)
85. Brose, M.S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J.A.; Albelda, S.M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P.A.; Wooster, R.; Stratton, M.R.; Weber, B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 2002, 62, 6997-7000. (Pubitemid 35424092)
86. Kozuki, T.; Kiura, K.; Ueoka, H.; Tabata, M.; Date, H.; Hamazaki, S.; Bessho, A.; Tanimoto, M. Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung. Anticancer Res., 2004, 24, 393-396. (Pubitemid 38279737)
87. Toyooka, S.; Uchida, A.; Shigematsu, H.; Soh, J.; Ogino, A.; Takata, M.; Kiura, K.; Ouchida, M.; Kosaka, T.; Aoe, M.; Mitsudomi, T.; Date, H. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. J. Thorac. Oncol., 2007, 2, 321-324. (Pubitemid 47181716)
88. Shepherd, C.; Puzanov, I.; Sosman, J.A. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr. Oncol. Rep., 2010, 12, 146-152.
89. Board, R.E.; Ellison, G.; Orr, M.C.; Kemsley, K.R.; McWalter, G.; Blockley, L.Y.; Dearden, S.P.; Morris, C.; Ranson, M.; Cantarini, M.V.; Dive, C.; Hughes, A. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br. J. Cancer, 2009, 101, 1724-1730.
90. Takezawa, K.; Okamoto, I.; Yonesaka, K.; Hatashita, E.; Yamada, Y.; Fukuoka, M.; Nakagawa, K. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res., 2009, 69, 6515-6521.
91. Sasaki, T.; Rodig, S.J.; Chirieac, L.R.; Janne, P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer, 2010, 46, 1773-1780.
92. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature, 2007, 448, 561-566. (Pubitemid 47206930)
93. Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E.J.; Rodig, S.J.; Chirieac, L.R.; Kwak, E.L.; Lynch, T.J.; Iafrate, A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 2009, 27, 4247-4253.
94. Solomon, B.; Varella-Garcia, M.; Camidge, D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol., 2009, 4, 1450-1454.
95. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; Kuwano, H.; Mitsudomi, T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., 2006, 12, 5764-5769. (Pubitemid 44629607)
96. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2, e73.
97. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Janne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352, 786-792. (Pubitemid 40271173)
98. Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.P.; Hughes, T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 2002, 99, 3472-3475. (Pubitemid 34525335)
99. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; Engen, J.R.; Wong, K.K.; Eck, M.J.; Gray, N.S.; Janne, P.A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.
100. Regales, L.; Gong, Y.; Shen, R.; de Stanchina, E.; Vivanco, I.; Goel, A.; Koutcher, J.A.; Spassova, M.; Ouerfelli, O.; Mellinghoff, I.K.; Zakowski, M.F.; Politi, K.A.; Pao, W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest., 2009, 119, 3000-3010.
101. Bean, J.; Riely, G.J.; Balak, M.; Marks, J.L.; Ladanyi, M.; Miller, V.A.; Pao, W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res., 2008, 14, 7519-7525.
102. Nguyen, K.S.; Kobayashi, S.; Costa, D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer, 2009, 10, 281-289.
103. Murray, S.; Dahabreh, I.J.; Linardou, H.; Manoloukos, M.; Bafaloukos, D.; Kosmidis, P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in nonsmall cell lung cancer: an analytical database. J. Thorac. Oncol., 2008, 3, 832-839.
104. Busser, B.; Sancey, L.; Josserand, V.; Niang, C.; Khochbin, S.; Favrot, M.C.; Coll, J.L.; Hurbin, A. Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation. Mol. Ther., 2010, 18, 536-543.
105. Ishikawa, N.; Daigo, Y.; Takano, A.; Taniwaki, M.; Kato, T.; Hayama, S.; Murakami, H.; Takeshima, Y.; Inai, K.; Nishimura, H.; Tsuchiya, E.; Kohno, N.; Nakamura, Y. Increases of amphiregulin and transforming growth factoralpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res., 2005, 65, 9176-9184. (Pubitemid 41507981)
106. Jacobs, B.; De Roock, W.; Piessevaux, H.; Van Oirbeek, R.; Biesmans, B.; De Schutter, J.; Fieuws, S.; Vandesompele, J.; Peeters, M.; Van Laethem, J.L.; Humblet, Y.; Penault-Llorca, F.; De Hertogh, G.; Laurent-Puig, P.; Van Cutsem, E.; Tejpar, S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol., 2009, 27, 5068-5074.
107. Chang, M.H.; Ahn, H.K.; Lee, J.; Jung, C.K.; Choi, Y.L.; Park, Y.H.; Ahn, J.S.; Park, K.; Ahn, M.J. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer, 2010.
108. Bao, R.; Lai, C.J.; Wang, D.G.; Qu, H.; Yin, L.; Zifcak, B.; Tao, X.; Wang, J.; Atoyan, R.; Samson, M.; Forrester, J.; Xu, G.X.; DellaRocca, S.; Borek, M.; Zhai, H.X.; Cai, X.; Qian, C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol. Cancer Ther., 2009, 8, 3296-3306.
109. Yano, S.; Wang, W.; Li, Q.; Matsumoto, K.; Sakurama, H.; Nakamura, T.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Nishioka, Y.; Uehara, H.; Mitsudomi, T.; Yatabe, Y.; Sone, S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res., 2008, 68, 9479-9487.
110. Seike, M.; Goto, A.; Okano, T.; Bowman, E.D.; Schetter, A.J.; Horikawa, I.; Mathe, E.A.; Jen, J.; Yang, P.; Sugimura, H.; Gemma, A.; Kudoh, S.; Croce, C.M.; Harris, C.C. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 12085-12090.
111. Weiss, G.J.; Bemis, L.T.; Nakajima, E.; Sugita, M.; Birks, D.K.; Robinson, W.A.; Varella-Garcia, M.; Bunn, P.A. Jr.; Haney, J.; Helfrich, B.A.; Kato, H.; Hirsch, F.R.; Franklin, W.A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol., 2008, 19, 1053-1059. (Pubitemid 351796329)
112. Kaira, K.; Takahashi, T.; Murakami, H.; Tsuya, A.; Nakamura, Y.; Naito, T.; Endo, M.; Yamamoto, N. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer, 2010, 67, 120-123.
113. Fukui, T.; Otani, S.; Hataishi, R.; Jiang, S.X.; Nishii, Y.; Igawa, S.; Mitsufuji, H.; Kubota, M.; Katagiri, M.; Masuda, N. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother. Pharmacol., 2010, 65, 803-806.
114. Tomizawa, Y.; Fujita, Y.; Tamura, A.; Shirai, M.; Shibata, S.; Kawabata, T.; Shibayama, T.; Fukai, S.; Kawahra, M.; Saito, R. Effect of gefitinib rechallenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer, 2010, 68, 269-272.
115. Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 2007, 7, 415-428. (Pubitemid 46809165)
116. Maeda, M.; Johnson, K.R.; Wheelock, M.J. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-tomesenchyme transition. J. Cell Sci., 2005, 118, 873-887. (Pubitemid 40484880)
117. Kim, H.J.; Litzenburger, B.C.; Cui, X.; Delgado, D.A.; Grabiner, B.C.; Lin, X.; Lewis, M.T.; Gottardis, M.M.; Wong, T.W.; Attar, R.M.; Carboni, J.M.; Lee, A.V. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol. Cell Biol., 2007, 27, 3165-3175. (Pubitemid 46581327)
118. Morgillo, F.; Woo, J.K.; Kim, E.S.; Hong, W.K.; Lee, H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res., 2006, 66, 10100-10111. (Pubitemid 44672064)
119. Lu, Z.; Jiang, G.; Blume-Jensen, P.; Hunter, T. Epidermal growth factorinduced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol. Cell Biol., 2001, 21, 4016-4031. (Pubitemid 32476463)
120. Yauch, R.L.; Januario, T.; Eberhard, D.A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T.Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C.Y.; O'Neill, V.; Amler, L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res., 2005, 11, 8686-8698. (Pubitemid 43005918)
121. Witta, S.E.; Gemmill, R.M.; Hirsch, F.R.; Coldren, C.D.; Hedman, K.; Ravdel, L.; Helfrich, B.; Dziadziuszko, R.; Chan, D.C.; Sugita, M.; Chan, Z.; Baron, A.; Franklin, W.; Drabkin, H.A.; Girard, L.; Gazdar, A.F.; Minna, J.D.; Bunn, P.A. Jr. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res., 2006, 66, 944-950. (Pubitemid 43165962)
122. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K.K.; Gibson, N.; Haley, J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res., 2005, 65, 9455-9462. (Pubitemid 41508014)
123. Yao, Z.; Fenoglio, S.; Gao, D.C.; Camiolo, M.; Stiles, B.; Lindsted, T.; Schlederer, M.; Johns, C.; Altorki, N.; Mittal, V.; Kenner, L.; Sordella, R. TGF-{beta} IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 15535-15540.
124. Cain, C.; Writer, S. Inflaming resistance to Tarceva. SciBX, 2010, 3, 10.1038/scibx.2010.1056.
125. Pao, W.; Wang, T.Y.; Riely, G.J.; Miller, V.A.; Pan, Q.; Ladanyi, M.; Zakowski, M.F.; Heelan, R.T.; Kris, M.G.; Varmus, H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med., 2005, 2, e17.
126. Felip, E.; Rojo, F.; Reck, M.; Heller, A.; Klughammer, B.; Sala, G.; Cedres, S.; Peralta, S.; Maacke, H.; Foernzler, D.; Parera, M.; Mocks, J.; Saura, C.; Gatzemeier, U.; Baselga, J. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin. Cancer Res., 2008, 14, 3867-3874.
127. Hirsch, F.R.; Varella-Garcia, M.; Cappuzzo, F.; McCoy, J.; Bemis, L.; Xavier, A.C.; Dziadziuszko, R.; Gumerlock, P.; Chansky, K.; West, H.; Gazdar, A.F.; Crino, L.; Gandara, D.R.; Franklin, W.A.; Bunn, P.A. Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol., 2007, 18, 752-760. (Pubitemid 46523281)
128. Jackman, D.M.; Miller, V.A.; Cioffredi, L.A.; Yeap, B.Y.; Janne, P.A.; Riely, G.J.; Ruiz, M.G.; Giaccone, G.; Sequist, L.V.; Johnson, B.E. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res., 2009, 15, 5267-5273.
129. Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A.C.; Ozburn, N.C.; Liu, D.D.; Bekele, B.N.; Herbst, R.S.; Wistuba, II, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res., 2007, 13, 2890-2896. (Pubitemid 46849563)
130. Ichihara, S.; Toyooka, S.; Fujiwara, Y.; Hotta, K.; Shigematsu, H.; Tokumo, M.; Soh, J.; Asano, H.; Ichimura, K.; Aoe, K.; Aoe, M.; Kiura, K.; Shimizu, K.; Date, H.; Shimizu, N. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer, 2007, 120, 1239-1247.
131. van Zandwijk, N.; Mathy, A.; Boerrigter, L.; Ruijter, H.; Tielen, I.; de Jong, D.; Baas, P.; Burgers, S.; Nederlof, P. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann. Oncol., 2007, 18, 99-103. (Pubitemid 46152507)
132. Varella-Garcia, M.; Mitsudomi, T.; Yatabe, Y.; Kosaka, T.; Nakajima, E.; Xavier, A.C.; Skokan, M.; Zeng, C.; Franklin, W.A.; Bunn, P.A. Jr.; Hirsch, F.R. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J. Thorac. Oncol., 2009, 4, 318-325.
133. Zhu, C.Q.; da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J.C.; Liu, N.; Zhang, T.; Marrano, P.; Whitehead, M.; Squire, J.A.; Kamel-Reid, S.; Seymour, L.; Shepherd, F.A.; Tsao, M.S. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol., 2008, 26, 4268-4275.
134. Lynch, T.J.; Fenton, D.; Hirsh, V.; Bodkin, D.; Middleman, E.L.; Chiappori, A.; Halmos, B.; Favis, R.; Liu, H.; Trepicchio, W.L.; Eton, O.; Shepherd, F.A. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol., 2009, 4, 1002-1009.
135. Schneider, C.P.; Heigener, D.; Schott-von-Romer, K.; Gutz, S.; Laack, E.; Digel, W.; Guschall, W.R.; Franke, A.; Bodenstein, H.; Schmidtgen, C.; Reck, M. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J. Thorac. Oncol., 2008, 3, 1446-1453.
136. Tiseo, M.; Rossi, G.; Capelletti, M.; Sartori, G.; Spiritelli, E.; Marchioni, A.; Bozzetti, C.; De Palma, G.; Lagrasta, C.; Campanini, N.; Camisa, R.; Boni, L.; Franciosi, V.; Rindi, G.; Ardizzoni, A. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67, 355-360.
137. Ahn, M.J.; Park, B.B.; Ahn, J.S.; Kim, S.W.; Kim, H.T.; Lee, J.S.; Kang, J.H.; Cho, J.Y.; Song, H.S.; Park, S.H.; Sohn, C.H.; Shin, S.W.; Choi, J.H.; Ki, C.S.; Park, C.K.; Holmes, A.J.; Janne, P.A.; Park, K. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced nonsmall cell lung cancer? Clin. Cancer Res., 2008, 14, 3860-3866.
138. Sasaki, H.; Endo, K.; Okuda, K.; Kawano, O.; Kitahara, N.; Tanaka, H.; Matsumura, A.; Iuchi, K.; Takada, M.; Kawahara, M.; Kawaguchi, T.; Yukiue, H.; Yokoyama, T.; Yano, M.; Fujii, Y. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J. Cancer Res. Clin. Oncol., 2008, 134, 569-577. (Pubitemid 351422610)
139. Wu, C.C.; Hsu, H.Y.; Liu, H.P.; Chang, J.W.; Chen, Y.T.; Hsieh, W.Y.; Hsieh, J.J.; Hsieh, M.S.; Chen, Y.R.; Huang, S.F. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208.
140. Cappuzzo, F.; Ligorio, C.; Janne, P.A.; Toschi, L.; Rossi, E.; Trisolini, R.; Paioli, D.; Holmes, A.J.; Magrini, E.; Finocchiaro, G.; Bartolini, S.; Cancellieri, A.; Ciardiello, F.; Patelli, M.; Crino, L.; Varella-Garcia, M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol., 2007, 25, 2248-2255. (Pubitemid 46954651)
141. Endoh, H.; Yatabe, Y.; Kosaka, T.; Kuwano, H.; Mitsudomi, T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol., 2006, 1, 629-634. (Pubitemid 47163949)
142. Zucali, P.A.; Ruiz, M.G.; Giovannetti, E.; Destro, A.; Varella-Garcia, M.; Floor, K.; Ceresoli, G.L.; Rodriguez, J.A.; Garassino, I.; Comoglio, P.; Roncalli, M.; Santoro, A.; Giaccone, G. Role of cMET expression in nonsmall- cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann. Oncol., 2008, 19, 1605-1612.
143. Lara-Guerra, H.; Waddell, T.K.; Salvarrey, M.A.; Joshua, A.M.; Chung, C.T.; Paul, N.; Boerner, S.; Sakurada, A.; Ludkovski, O.; Ma, C.; Squire, J.; Liu, G.; Shepherd, F.A.; Tsao, M.S.; Leighl, N.B. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 6229-6236.
144. Yasuda, H.; Soejima, K.; Nakayama, S.; Kawada, I.; Nakachi, I.; Yoda, S.; Satomi, R.; Ikemura, S.; Terai, H.; Sato, T.; Watanabe, H.; Naoki, K.; Hayashi, Y.; Ishizaka, A. Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer. Lung Cancer, 2010.
145. Takahashi, T.; Sonobe, M.; Kobayashi, M.; Yoshizawa, A.; Menju, T.; Nakayama, E.; Mino, N.; Iwakiri, S.; Sato, K.; Miyahara, R.; Okubo, K.; Manabe, T.; Date, H. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann. Surg. Oncol., 2010, 17, 889-897.
146. Murakami, S.; Yokose, T.; Saito, H.; Sakuma, Y.; Matsukuma, S.; Hasegawa, C.; Kondo, T.; Oshita, F.; Ito, H.; Tsuboi, M.; Nakayama, H.; Kameda, Y.; Noda, K.; Yamada, K. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer, 2010, 69, 361-364.
147. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J.M.; Yuan, J.; Bakalarski, C.E.; Villen, J.; Kornhauser, J.M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S.P.; Gu, T.L.; Polakiewicz, R.D.; Rush, J.; Comb, M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131, 1190-1203. (Pubitemid 350235027)
148. Boland, J.M.; Erdogan, S.; Vasmatzis, G.; Yang, P.; Tillmans, L.S.; Johnson, M.R.; Wang, X.; Peterson, L.M.; Halling, K.C.; Oliveira, A.M.; Aubry, M.C.; Yi, E.S. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum. Pathol., 2009, 40, 1152-1158.
149. Shinmura, K.; Kageyama, S.; Tao, H.; Bunai, T.; Suzuki, M.; Kamo, T.; Takamochi, K.; Suzuki, K.; Tanahashi, M.; Niwa, H.; Ogawa, H.; Sugimura, H. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer, 2008, 61, 163-169.
150. Fukuyoshi, Y.; Inoue, H.; Kita, Y.; Utsunomiya, T.; Ishida, T.; Mori, M. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br. J. Cancer, 2008, 98, 1536-1539. (Pubitemid 351652334)
151. Wong, D.W.; Leung, E.L.; So, K.K.; Tam, I.Y.; Sihoe, A.D.; Cheng, L.C.; Ho, K.K.; Au, J.S.; Chung, L.P.; Pik Wong, M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115, 1723-1733.
152. Zhang, X.; Zhang, S.; Yang, X.; Yang, J.; Zhou, Q.; Yin, L.; An, S.; Lin, J.; Chen, S.; Xie, Z.; Zhu, M.; Wu, Y.L. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol. Cancer, 2010, 9, 188.
153. Lin, E.; Li, L.; Guan, Y.; Soriano, R.; Rivers, C.S.; Mohan, S.; Pandita, A.; Tang, J.; Modrusan, Z. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res., 2009, 7, 1466-1476.
154. Perner, S.; Wagner, P.L.; Demichelis, F.; Mehra, R.; Lafargue, C.J.; Moss, B.J.; Arbogast, S.; Soltermann, A.; Weder, W.; Giordano, T.J.; Beer, D.G.; Rickman, D.S.; Chinnaiyan, A.M.; Moch, H.; Rubin, M.A. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia, 2008, 10, 298-302. (Pubitemid 351328588)
155. Koivunen, J.P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A.J.; Choi, H.G.; Kim, J.; Chiang, D.; Thomas, R.; Lee, J.; Richards, W.G.; Sugarbaker, D.J.; Ducko, C.; Lindeman, N.; Marcoux, J.P.; Engelman, J.A.; Gray, N.S.; Lee, C.; Meyerson, M.; Janne, P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res., 2008, 14, 4275-4283.
156. Rodig, S.J.; Mino-Kenudson, M.; Dacic, S.; Yeap, B.Y.; Shaw, A.; Barletta, J.A.; Stubbs, H.; Law, K.; Lindeman, N.; Mark, E.; Janne, P.A.; Lynch, T.; Johnson, B.E.; Iafrate, A.J.; Chirieac, L.R. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res., 2009, 15, 5216-5223.
157. Takeuchi, K.; Choi, Y.L.; Soda, M.; Inamura, K.; Togashi, Y.; Hatano, S.; Enomoto, M.; Takada, S.; Yamashita, Y.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y.; Mano, H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res., 2008, 14, 6618-6624.
158. Inamura, K.; Takeuchi, K.; Togashi, Y.; Hatano, S.; Ninomiya, H.; Motoi, N.; Mun, M.Y.; Sakao, Y.; Okumura, S.; Nakagawa, K.; Soda, M.; Choi, Y.L.; Mano, H.; Ishikawa, Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol., 2009, 22, 508-515.
159. Martelli, M.P.; Sozzi, G.; Hernandez, L.; Pettirossi, V.; Navarro, A.; Conte, D.; Gasparini, P.; Perrone, F.; Modena, P.; Pastorino, U.; Carbone, A.; Fabbri, A.; Sidoni, A.; Nakamura, S.; Gambacorta, M.; Fernandez, P.L.; Ramirez, J.; Chan, J.K.; Grigioni, W.F.; Campo, E.; Pileri, S.A.; Falini, B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol., 2009, 174, 661-670.
160. Osoegawa, A.; Nosaki, K.; Miyamoto, H.; Kometani, T.; Hirai, F.; Ondo, K.; Seto, T.; Sugio, K.; Choi, Y.L.; Soda, M.; Mano, H.; Ichinose, Y. Incidentally proven pulmonary "ALKoma". Intern. Med., 2010, 49, 603-606.
161. Hirano, S.; Sano, K.; Morii, S.; Morita, A.; Takeda, Y.; Uruga, K.; Sugiyama, H.; Kobayashi, N.; Kudo, K. [A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired]. Gan To Kagaku Ryoho, 2009, 36, 1333-1336.
162. Yano, S.; Nakataki, E.; Ohtsuka, S.; Inayama, M.; Tomimoto, H.; Edakuni, N.; Kakiuchi, S.; Nishikubo, N.; Muguruma, H.; Sone, S. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res., 2005, 15, 107-111. (Pubitemid 40825922)
163. Wu, S.G.; Shih, J.Y.; Yu, C.J.; Yang, P.C. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J. Thorac. Oncol., 2008, 3, 451-452.
164. Gridelli, C.; Maione, P.; Galetta, D.; Colantuoni, G.; Del Gaizo, F.; Ferrara, C.; Guerriero, C.; Nicolella, D.; Rossi, A. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J. Thorac. Oncol., 2007, 2, 758-761. (Pubitemid 47357532)
165. Vasile, E.; Tibaldi, C.; Chella, A.; Falcone, A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J. Thorac. Oncol., 2008, 3, 912-914.
166. Lee, D.H.; Kim, S.W.; Suh, C.; Yoon, D.H.; Yi, E.J.; Lee, J.S. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann. Oncol., 2008, 19, 2039-2042.
167. Katayama, T.; Shimizu, J.; Suda, K.; Onozato, R.; Fukui, T.; Ito, S.; Hatooka, S.; Sueda, T.; Hida, T.; Yatabe, Y.; Mitsudomi, T. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J. Thorac. Oncol., 2009, 4, 1415-1419.
168. Wong, M.K.; Lo, A.I.; Lam, B.; Lam, W.K.; Ip, M.S.; Ho, J.C. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother. Pharmacol., 65, 1023-1028.
169. Costa, D.B.; Nguyen, K.S.; Cho, B.C.; Sequist, L.V.; Jackman, D.M.; Riely, G.J.; Yeap, B.Y.; Halmos, B.; Kim, J.H.; Janne, P.A.; Huberman, M.S.; Pao, W.; Tenen, D.G.; Kobayashi, S. Effects of erlotinib in EGFR mutated nonsmall cell lung cancers with resistance to gefitinib. Clin. Cancer Res., 2008, 14, 7060-7067.
170. Wong, A.S.; Soong, R.; Seah, S.B.; Lim, S.W.; Chuah, K.L.; Nga, M.E.; Chin, T.M.; Soo, R.A. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 400-404. (Pubitemid 351489481)
171. Cho, B.C.; Im, C.K.; Park, M.S.; Kim, S.K.; Chang, J.; Park, J.P.; Choi, H.J.; Kim, Y.J.; Shin, S.J.; Sohn, J.H.; Kim, H.; Kim, J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol., 2007, 25, 2528-2533. (Pubitemid 47041225)
172. Takamochi, K.; Suzuki, K.; Bashar, A.H.; Yajima, K.; Mochizuki, T.; Itaya, T.; Funai, K. Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J. Med. Case Reports, 2007, 1, 138.
173. Kurata, T.; Tamura, K.; Kaneda, H.; Nogami, T.; Uejima, H.; Asai Go, G.; Nakagawa, K.; Fukuoka, M. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann. Oncol., 2004, 15, 173-174.
174. Kim, H.K.; Ahn, M.I.; Yoo, J.; Kim, C.H.; Yang, H.J.; Shim, B.Y. Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman. Cancer Res. Treat., 2007, 39, 37-39.
175. Chang, J.W.; Chou, C.L.; Huang, S.F.; Wang, H.M.; Hsieh, J.J.; Hsu, T.; Cheung, Y.C. Erlotinib response of EGFR-mutant gefitinib-resistant nonsmall- cell lung cancer. Lung Cancer, 2007, 58, 414-417. (Pubitemid 350051498)
176. Walther, J.C.; Khorshid, M.; Gaya, A.; Plowman, P.N. Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash. Clin. Oncol. (R. Coll. Radiol.), 2006, 18, 637-639.
177. Gounant, V.; Wislez, M.; Poulot, V.; Khalil, A.; Lavole, A.; Cadranel, J.; Milleron, B. Subsequent brain metastasis responses to epidermal growthfactor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer, 2007, 58, 425-428. (Pubitemid 350064403)
178. Viswanathan, A.; Pillot, G.; Govindan, R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2005, 50, 417-418.
179. Zhou, Z.T.; Xu, X.H.; Wei, Q.; Lu, M.Q.; Wang, J.; Wen, C.H. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother. Pharmacol., 2009, 64, 1123-1127.
180. Garfield, D.H. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J. Clin. Oncol., 2005, 23, 7738-7740. (Pubitemid 46291838)
181. Sim, S.H.; Han, S.W.; Oh, D.Y.; Lee, S.H.; Kim, D.W.; Im, S.A.; Chung, D.H.; Kim, T.Y.; Lee, J.S.; Kim, Y.W.; Heo, D.S.; Bang, Y.J. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer, 2009, 65, 204-207.
182. Yoshimoto, A.; Inuzuka, K.; Kita, T.; Kawashima, A.; Kasahara, K. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am. J. Med. Sci., 2007, 333, 221-225. (Pubitemid 46624812)
183. Takeda, M.; Okamoto, I.; Makimura, C.; Fukuoka, M.; Nakagawa, K. Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J. Thorac. Oncol., 2010, 5, 1103-1104.
184. Chang SC, Chang CY, Chen CY, Yu CJ. Successful erlotinib rechallenge after gefitinib acute interstitial pneumonia. J. Thorac. Oncol., 2010, 5, 1105-1106.